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Summary. The product of independent beta probabilities escalation design for dual agent phase
I dose escalation trials is a Bayesian model-free approach for identifying multiple maximum tol-
erated dose combinations of novel combination therapies. Despite only being published in 2015,
the design has been implemented in at least two oncology trials. However, these trials require
patients to have completed follow-up before clinicians can make dose escalation decisions. For
trials of radiotherapy or advanced therapeutics, this may lead to impractically long trial durations
due to late-onset treatment-related toxicities.We extend the product of independent probabilities
escalation design to use censored time-to-event toxicity outcomes for making dose escalation
decisions. We show via comprehensive simulation studies and sensitivity analyses that trial
duration can be reduced by up to 35%, particularly when recruitment is faster than expected,
without compromising on other operating characteristics.
Keywords: Adaptive designs; Bayesian methods; Clinical trials; Dose escalation; Model-free
approach; Time to event
1. Introduction
The majority of anticancer therapeutic strategies consist of giving patients two or more treat-
ments together to provide improved treatment effects relative to individual therapies given alone.
In phase I trials of novel combination therapies, the aim is to identify one or more maximum
tolerated dose combinations (MTDCs), i.e. one or more dose combinations with an expected
probability of causing a severe drug-related adverse event equal to or close to a target of in-
terest, known as the target toxicity level (TTL). Once identiﬁed, larger comparative trials are
conducted to compare the efﬁcacy of the MTDC(s) of the new combined treatment regimen
with standard care, in the hope of improving patient response and survival outcomes.
Similarly to phase I trials formonotherapies, trials of two treatments combined are conducted
as dose escalation studies. In these, patients are allocated to a dose combination and observed
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over time, with the number and severity of adverse events recorded. On the basis of these
data, the next cohort of patients may receive the same combination or a different combination;
if the current dose combination is considered tolerable (e.g. no adverse events reported), the
next cohort may receive a combination with only one drug increased, or both drugs increased
simultaneously. By gradually exploring the dose–toxicity grid, we aim to identifyMTDCs while
minimizing the chance of overdosing patients in the trial.
Several approaches for designing phase I dose escalation studies on drug combinations have
been proposed (Harrington et al., 2013); these include rule-based and model-based trials. Man-
der and Sweeting (2015) proposed a probabilistic model-free approach: the product of indepen-
dent probabilities escalation (PIPE) design. The PIPE design does not assume a model for the
dose–toxicity surface; each dose combination is assigned a beta prior distribution, independent
of all other combinations,which is updatedwith trial data.The tail probabilities that each combi-
nation are above theTTLare calculated andused to estimate the chance that a particular contour
dividing the dose–toxicity surface into two areas of tolerable and intolerable combinations is the
true maximum tolerated contour (MTC). This approach gives sensible estimation of toxicity
risks when the dose–toxicity surface cannot be well approximated by a model (e.g. if the surface
is asymmetric) and, unlike many rule-based designs, allows borrowing of information across
dose combinations. The PIPE design has been implemented in practice in at least two trials:
these include a study of the monoclonal antibody emactuzumab and RO7009789 in combina-
tion in participants with advanced solid tumours (ClinicalTrials.gov identiﬁer NCT02760797),
and ORCA-2, a phase I study of olaparib in addition to cisplatin-based chemoradiotherapy
for patients with advanced squamous cell head and neck cancer (ClinicalTrials.gov identiﬁer
NCT02308072). Since radiotherapy is used in the ORCA-2 trial, late-onset treatment-related
toxicities are expected and the dose limiting toxicity (DLT) observation window is 14 weeks
from the ﬁrst administration of olaparib.
One requirement ofmany phase I trials is that the end point (often a binary outcome denoting
DLT or no DLT) must be observed before making dose escalation decisions. Trials with a
long DLT observation window, e.g. radiotherapy trials such as ORCA-2, may have a long
planned duration and therefore a large cost. Furthermore, the underlying patient population
may change over time if the trial is planned to last a long time; patient drift may affect which
combinations are considered to be tolerable and intolerable (Villar et al., 2015). In addition,
rapid recruitment may mean that we cannot assign suitable patients to trial treatments because
we must wait for outcomes to be obtained from current patients. Patients waiting may have
their treatment delayed, or in the worst case may never receive treatment because of death.
To overcome these problems, time-to-event (TITE) outcomes have been proposed for use in
single-agent dose escalation studies (Cheung and Chappell, 2000; Braun, 2006; Ivanova et al.,
2016). Rather than an outcome of DLT or no DLT, a patient’s outcome measured at any
point during their DLT observation window is a function of the time for which they have yet
to be observed, conditional on the patient’s not yet experiencing a DLT. Wages et al. (2013)
applied the time-to-event–continual reassessment method (TITE–CRM) design (Cheung and
Chappell, 2000) to dual agent trials by exploiting partial orders of dose–toxicity probabilities per
dose combination. They could shorten trial durations by 84–89% in several scenarios, in which
only one combination was the MTDC and patients were treated when they arrived. However,
multiple MTDCs may exist when combining treatments and a one-parameter CRM model is
insufﬁcient to identify multiple MTDCs. Furthermore, the number of possible partial orders
increases exponentially as the number of dose levels per agent is increased.
We propose an approach for extending the model-free PIPE design by using a TITE outcome
measure. We use the proportion of a patient’s DLT observation window that has passed since
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the time of treatment administration, with DLT unobserved, as a form of censored toxicity
response. Even if some patients have not completed follow-up, dose escalation decisions can
still be made and trial duration can be reduced. We call this proposed method the TITE–
PIPE method. Section 2 outlines the TITE–PIPE methodology and in Section 3 we describe
and present comparative simulation studies to compare the performance of the TITE–PIPE
against the PIPE method with respect to experimentation, recommendation and trial duration.
In Section 5 we conclude with a discussion of our ﬁndings and provide practical considerations
as well as areas for future research.




Consider a dual agent phase I trial of J dose levels of agent A, {a1, : : : ,aJ}, and K dose levels
of agent B, {b1, : : : , bK}. Let Yi,t be a binary random variable that takes value 1 if at time t′ t
patient i has experienced a DLT, and 0 otherwise. If Yi,t = 1, then Yi,t′ = 1 ∀ t′ t. Let ti0 be
the time at which patient i begins treatment, and let Ui 0 be a random variable denoting
the time from ti0 at which patient i experiences a DLT. We assume that each patient’s DLT
observation window is T time units. Then, for DLT observation period [ti0, ti0 +T ], the random
variable Yi,ti0+T |Ui, i.e. the indicator of whether patient i has had aDLT by the end of their DLT
observation period conditionally on their time to DLT being equal to Ui, is
Yi,ti0+T |Ui =
{
1 if Ui ∈ [0,T ]
0 otherwise,
and therefore the distribution of Yi,ti0+T is Bernoulli with probability P.Ui ∈ [0,T ]/. Ultimately
our aim is to estimate the risk that a patient experiences a DLT in their DLT observation
window [ti0, ti0 +T ]. However, we would also like to consider what the risk that Yi,ti0+T equals
1 is when we have only observed data up to any time t ∈ [ti0, ti0 +T ] without observing Ui, i.e.
P.Ui ∈ [t − ti0,T ]|Ui t − ti0/. Therefore, we may use the censored time to DLT for patient i part
way through their DLT observation period to help us in this.
2.1. Weighted outcomes
Let wi,t be the weighted outcome for patient i who begins treatment at time ti0 and is observed
at time t ∈ [ti0, ti0 +T ]. We may deﬁne wi,t as
wi,t =
{
1 if yi,t =1 and t ti0 +T ,
φ.t; ti0,T/ if yi,t =0 and t ti0 +T , .1/
where 0φ.t; ti0,T/ 1 ∀ t and φ.t; ti0,T/ is decreasing with increasing t. So, if patient i has a
DLT by time t ∈ [ti0, ti0 +T ], then wi,t =1. Conversely, if patient i has not had a DLT observed
by time ti0 +T , then wi,ti0+T = 0. Otherwise, non-observance of a DLT at time t ∈ [ti0, ti0 +T ]
gives wi,t =φ.t; ti0,T/→ 0 as t → ti0 +T . At time ti0 + ξ for small ξ, we may want to have wi,t
close to 1, as we are assigning patient i to dose combination .aj,bk/ with the belief that, at time
ti0, dose combination .aj, bk/ has DLT probability close to the TTL, and escalation to higher
dose combinations for patient i+1 is not yet advisable. In the TITE–CRM design, Cheung and
Chappell (2000) proposed the use of a uniformly decreasing weight function, i.e.
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Fig. 1. Adaptive weight function ( ) and uniform weight function ( ) (DLT times ( ) alter the slope
of the adaptive weight function): (a) uniformly distributed; (b) early onset; (c) late onset; (d) very early or very
late
φ.t; ti0,T/=1− t − ti0
T
, .2/
such that, in the absence of a DLT, the rate of change in the weighted outcome is constantly





, ∀ t ∈ [ti0, ti0 +T ]:
An alternative weight function that was proposed by Cheung and Chappell (2000) adapted
weighted outcomes dependent on whether previous DLTs had been observed towards the start
or end of the observation window. If more DLTs are observed towards the end of the interval,
then a higher weight is given to a patient who has yet to have a DLT and not reached the latter
part of the observation window (relative to the uniform case in equation (2)). Similarly, if the
majority of DLTs are observed at the start of the observation window, a patient’s weighted
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outcome towards the end of the DLT observation window will be lower relative to the uniform
case. Speciﬁcally, for the set of z ordered DLT times Uz ={u.1/,u.2/, : : : ,u.z/} that occur in the
DLT observation window such that 0≡u.0/ <u.1/: : :u.z/ <u.z+1/ ≡T ,
φ.t; ti0,T ,Uz/=1− 1
z+1
(




where κ=max0hz{h : t − ti0u.h/}. Fig. 1 shows examples of both the uniformly decreasing
and adaptive weight functions based on different time-to-toxicity distributions during the DLT
observation window.
2.2. Posterior dose limiting toxicity probabilities
Regardless of the choice of weighting function, we may use the following approach to incor-
porate censored DLT outcomes into posterior estimates for the probability of DLT per dose
combination.Assume that our prior uncertainty of the probability ofDLTπjk for dose combina-
tion .aj,bk/ can be represented by a beta(rjk,0, sjk,0) distribution. As per Mander and Sweeting
(2015), we specify rjk,0 and sjk,0 such that the prior median is equal to a prespeciﬁed value πˆjk
(i.e., for beta cumulative distribution function B.v; rjk,0, sjk,0/, B.πˆjk; rjk,0, sjk,0/=0:50) and the
effective sample size at dose combination .aj, bk/ is rjk,0+ sjk,0=1=.JK/. Therefore, the effective
sample size across all dose combinations is equal to one patient. Assume that njk,t patients have
been assigned to dose combination .aj, bk/ at time t, and these patients’ identiﬁers are contained
in the indexing set Ijk,t . Let Rjk,t =Σi∈Ijk, twi,t and Sjk,t =Σi∈Ijk,t .1−wi,t/=njk,t −Rjk,t be the
total number of weighted DLTs and weighted non-DLTs observed for patients in Ijk,t . The
likelihood function arising from these data is binomial, speciﬁcally
L.πjk|Rjk,t ,Sjk,t/∝πRjk, tjk .1−πjk/Sjk, t :
Since the beta prior is conjugate for the binomial likelihood function, the posterior probability
distribution of πjk at time t is also beta distributed, i.e. πjk ∼ beta.rjk,0 + Rjk,t , sjk,0 + Sjk,t/.
This provides a working model for each πjk, which are independent. Therefore no assumptions
are made regarding the marginal dose–toxicity relationship of each agent, speciﬁcally that the
marginal probabilities are monotonically increasing, i.e. πjkπ.j+1/k and πjkπj.k+1/. Mono-
tonicity is introduced through the MTC.
2.3. Posterior contour probabilities
As proposed by Mander and Sweeting (2015), we may use the posterior distributions of πjk to
construct anMTC,which satisﬁes the assumption ofmonotonicity. Amonotonic contourC can
be deﬁned by a J ×K binarymatrix, such thatC[j, k]=1 if dose combination .aj,bk/ is above the
contour (i.e. it is considered intolerable) andC[j, k]=0 if it is below (i.e. it is considered tolerable).
Let Ft be the set of all trial data available at time t, with Fjk,t ⊆Ft being the set of all data
available at dose combination .aj, bk/ at time t (i.e. Fjk,t = {∪i∈Ijk,t .wi,t ,yi,t/}; Ft =∪j,kFjk,t).
Let p.Fjk,t/ be the posterior probability that the toxicity risk at dose combination .aj,bk/ at
time t is less than TTL θ, i.e.
p.Fjk,t/=P.πjkθ|Fjk,t , rjk,0, sjk,0/=F.θ;Fjk,t , rjk,0, sjk,0/: .4/
Let r0 and s0 be the vectors of prior hyperparameters. A general formula for the probability that
the MTC is the contour deﬁned by matrix Cl is
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Here Cl belongs to C = {Cl : l = 1, : : : , . J +KJ /}: the set of all contours that do not violate the
marginal assumptions ofmonotonicity.Assuming that theMTCmust be oneof thesemonotonic













Patient allocation to a dose combination can follow similar procedures as speciﬁed by Mander
and Sweeting (2015). However, with the TITE–PIPE method we do not necessarily need to
wait for a patient’s follow-up to be complete before allocating doses for the next patient(s). We
shall assume the following set-up. The study starts at time t =0, when the ﬁrst patient enters. A
minimum of c patients must be dosed at a combination before experimentation elsewhere can
take place, and patients are followed up for a maximum of T time units (e.g. a week or amonth).
Under theTITE–PIPEdesign, though patients enter the study on their arrival time, regardless of
whether previous patient have completed follow-up or not, we employ a constraint that the ﬁrst
c patients in the trial (who are given the lowest dose combination .a1,b1/) must have completed
follow-up before new patients can enter the study. For each variant of the TITE–PIPE method,
we specify two allocation criteria that may be used.
(a) Completed dose: at least c patients must have completed their follow-up on a particular
dose combination before any more patients can be assigned to other dose combinations.
We denote this the TITE–PIPE–C criterion.
(b) Ondose: at least c patientsmust have been assigned to a dose combination before anymore
patients can be assigned to other dose combinations. We denote this the TITE–PIPE–O
criterion.
Under the TITE–PIPE–O design, c patients may be assigned to a dose combination and
then, immediately after, a decision can be made on where to dose the next patient; this may
not be ethical, but it is worthy of investigation (Senn et al., 2007; Bird et al., 2017). Under
the TITE–PIPE–C design, though we cannot make a dose escalation decision for the next
patient until c patients have completed their follow-up, if another patient is recommended to
the same combination (i.e. c + 1 patients are now on the current dose combination), we may
make decisions on where to dose future patients midway through the follow-up of patient c+1.
This satisﬁes ethical constraints (i.e. we have at least c patients’ worth of complete follow-up
data on the combination), but the trial duration may be reduced relative to the PIPE design
where all patients must have completed follow-up before escalation decisions are made. Under
both the TITE–PIPE–C and TITE–PIPE–O designs, if two or more patients arrive at the same
time, then admissible dose assignments are calculated after each individual patient has been
assigned to treatment; this was also undertaken in a trial of clofarabine in combination with
fractionated gemtuzumab ozogamicin in patients with refractory or relapsed acute myeloid
leukaemia (Foster et al., 2012; Ivanova et al., 2016). Fig. 2 illustrates how the trial entry and




Fig. 2. Example arrival and trial entry times from one simulated trial (patients arriving as a Poisson process
with mean 1.25; same random-number seed used across designs) (}, recruitment time; , start time; ,
follow-up; , DLT): for the PIPE design ((a)) each patient must have completed follow-up or have a confirmed
DLT reported before the next patient (if one has been recruited) can enter the study; for both the TITE–PIPE–C
((b)) and TITE–PIPE–O ((c)) designs, the first patient on study is required to have completed follow-up before
more patients are assigned to dose combinations; for the TITE–PIPE–C design, at least one patient per
combination must have completed follow-up before future patients can be assigned to dose combinations;
otherwise (and for the TITE–PIPE–O design), patients can enter the trial on arrival
arrival process works under each design (PIPE, TITE–PIPE–C andTITE–PIPE–O) for a cohort
size of one patient.
When we are ready to allocate patients to a combination, dose combinations are selected on
the basis of the following rules (Mander and Sweeting, 2015).
(a) Neighbouring dose combinations; escalation can be to doses that are within at most one
dose level of the previously experimented combination.
(b) Diagonal dose escalation (increasing doses of both drugs simultaneously) is permitted.
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(c) Closest dose combinations to the estimated MTC; admissible dose combinations for the
next cohort are those that are closest to the MTC (see Mander and Sweeting (2015) for
further details).
(d) Minimum sample size for ties; if multiple dose combinations are permitted, then choose
the combination with the fewest patients assigned to it. If there are still multiple com-
binations to choose from after these rules, the next patient is randomly assigned to one
such combination with equal probability.
2.5. Early termination
The trial is terminated eitherwhen themaximum sample size is reached, or if one of the following
stopping rules is satisﬁed.
Let Gjk,t be the set of all available trial data collected from patients who have completed
their follow-up (either had a DLT, or not had a DLT during their entire DLT observation
window) at dose combination .aj, bk/, i.e. Gjk,t ={∪i∈Ijk, t .wi,t ,yi,t/ : .wi,t ,yi,t/= .0, 0/∪yi,t =1}.
Let Gt =∪j,kGjk,t and q˜unsafe.Gt/ be the probability that the monotonic contour deﬁning all
dose combinations as unsafe, denoted Cunsafe, is the MTC (computed by using equation (6),
conditionally on complete follow-up data only). The trial is terminated early if q˜unsafe.Gt/ ,
where  is some threshold to be calibrated before the trial. In words, the trial is terminated early
if, using completed follow-up data only, the probability that the lowest dose combination is
above the MTC is at least . Only data from patients who have completed follow-up are used
to mitigate stopping early when several patients are still in observation; if they were not to
experience DLT, the trial could have continued.
Furthermore, we adopt a safety rule which is similar to that of Ivanova et al. (2016); if the
trial is deemed safe to continue by the aforementioned stopping rule (q˜unsafe.Gt/< ), but the
inclusion of data frompatients who are currently in observationmeans that all combinations are
inadmissible for the next patient, we wait until all patients who are currently under observation
have completed their follow-up. Mathematically, we say that dose combination .aj,bk/ is inad-
missible if ζjk.Ft/=ΣCl∈CCl.j, k/q˜l.Ft/ ; if ζjk.Ft/  ∀ j, k, recruitment is suspended until
all patients on trial have completed follow-up.Wemay then reassesswhether to terminate the trial
or not by using q˜unsafe.Gt/ and, if the trial is to continue, decide what combination the next pa-
tient should receive. This prevents stopping the trial on the basis of incomplete data and enables
a thorough assessment of the safety of the dose combinations before enrolling future patients.
2.6. Maximum tolerated dose combinations
At the end of the trial, say time t = tÅ, the modal MTC CÅtÅ =arg maxCl∈C{q˜l.GtÅ /} is estimated.
All dose combinations that lie closest to CÅtÅ from below that have been experimented on are
declared as MTDCs (Mander and Sweeting, 2015).
3. Simulation study
We now compare the original PIPE design, where new patients are admitted either once a DLT
has been observed in the previous patient, or the previous patient has completed their follow-
up period, with the TITE–PIPE–C and TITE–PIPE–O designs via simulation. In our studies
patients will be observed for T =1 time unit; if patient i enters the study at time 13:2 they will
be followed up until time 14:2, or until a DLT is observed, whichever occurs ﬁrst.
For our simulationswe use the seven dose–toxicity scenarios thatwere presented as simulation
2 in Mander and Sweeting (2015) (4×4 dose–toxicity grids also used by Braun and Jia (2013)).
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Table 1. Dose–toxicity scenarios for the simulation study†
†Combinations marked in italics have a DLT probability of
20% ± 2%. The MTC is shown as a line bisecting the dose–
toxicity grid.
We assume a priori median dose–toxicity values that are shown in scenario A (Table 1). The
TTL θ is 0:20. The threshold  at which doses are considered inadmissible (and also for early
termination of the trial) is calibrated to be 0:80, such that the trial is terminated if the ﬁrst two
patients, who are both treated at combination .a1,b1/, experience DLTs.
3.1. Dose–toxicity models
We consider three models for dose–toxicity, which simulate onset of toxicity as uniformly dis-
tributed, early onset or late onset. Similarly to work by Cheung and Chappell (2000) and Braun
(2006), these are as follows.
(a) Uniform (conditional uniform model):
(i) generate a random variable to determine whether patient i has a DLT;
(ii) if patient i does have a DLT, generate that patient’s time from treatment initiation to
DLT, Ui, from a uniform distribution over the interval [0,T ].
(b) Early onset (Pareto model): the time from treatment initiation to DLT for patient i is
Pareto distributed with a mode of 0:20 time units and scale parameter chosen per dose
combination so that the cumulative distribution function at time T is that combination’s
toxicity probability.
(c) Late onset (Weibull model): the time from treatment initiation to DLT for patient i is
Weibull distributed with a ﬁxed shape parameter of 4 and scale parameters chosen per
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Fig. 3. (a) Probability distribution function and (b) cumulative distribution function of uniform ( ),
Weibull ( ) and Pareto ( ) distributions for time to toxicity over DLT observation window [0, 1] (true
DLT probability at a dose combination of 0.20)
combination so that the cumulative distribution function at time T is that dose combina-
tion’s toxicity probability.
Fig. 3 shows the probability distribution functions and cumulative distribution functions
for the time-to-toxicity distributions under the uniform, Pareto and Weibull models that are
speciﬁed above.
Arrival times of patients are generated from a Poisson process with rate λ (the average number
of patients expected per time unit), with λ∈{0:5, 1, 2}.With three arrival rates and three toxicity
generation models, we have nine simulation environments per dose–toxicity scenario. For each
simulation environment,we investigate the performance of the PIPE,TITE–PIPE–CandTITE–
PIPE–O methods; for each TITE–PIPE approach we compare the uniform weighting function
(equation (2)) and the adaptive weighting function (equation (3)). We simulate 2000 trials per
simulation environment, using a maximum sample size of 40 patients.
3.2. Operating characteristics to compare
We compare the three designs and allocation rules by using the following operating character-
istics:
(a) experimentation percentages, i.e. the percentage of patients who are assigned to dose
combinations within a speciﬁc DLT probability range;
(b) MTDC recommendation percentages, i.e. the probability that, at the end of the trial, dose
combinations within a speciﬁc DLT probability range are identiﬁed as MTDCs (multiple
combinations may be recommended);
(c) trial duration (the time until trial is terminated or the last patient completes follow-up);
(d) sample size (since some trials may terminate early).
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3.3. Computational set-up
Simulations were undertaken in R by using code adapted from the pipe.design package
(Sweeting, 2016) (functions incorporated in the latest version of the package). We use the same
sequence of random seeds between each simulation environment to provide comparable oper-
ating characteristics.
4. Results
4.1. Illustrative single trial
Before presenting the results from the simulation study, we provide a single illustrative trial of
40 patients (Fig. 4). 16 dose combinations formed from four dose levels each of drug A and
drug B were under investigation, with the aim of targeting one or more MTDCs with θ=0:20.
Patient arrival times were simulated as a Poisson process with rate λ=2 (i.e. an average arrival
rate of two patients per time unit), and patients were followed up for T =1 time units. DLTs and
their times were simulated from scenario A under a conditional uniform model, with uniform
weighting assigned to unobserved DLTs. We conducted this trial by using the TITE–PIPE–C
method and required two patients to have completed treatment on a dose combination before
another combination may be considered for exploration.
No DLTs were observed in the ﬁrst four patients (two on .a1,b1/; two on .a2,b2/). Combi-
nation .a3,b2/ was given to two new patients, one of whom experienced DLT. The modal MTC
and safety constraint were updated and patients 7 and 8 were given .a4,b1/; this combination is
closest to theMTC and admissible. At t =4:93, patients 7 and 8 completed their follow-up (with
no DLTs occurring), and patients 9 and 10 are allocated to .a4,b1/ and .a3,b1/ respectively.
Since two patients are required at each dose level in our example trial, patient 11 also received
.a3,b1/. After these three patients completed their DLT follow-up at t =5:93 (n=11), patient 12
was allocated to .a3, b2/; this combination was below the safety contour after 11 patients and
closest to the modal MTC.
At t =12:37, 20 patients have been treated. Because of rapid recruitment, two patients were
available for treating at this time. Therefore patient 21 was administered .a1,b4/ and the MTC
re-estimated (similarly to that of the clofarabine plus fractionated gemtuzumab ozogamicin
trial (Foster et al., 2012)). Patient 22 was given .a1,b3/, as it was admissible and at least two
patients had previously completed treatment at that dose. By t = 12:78, just before patient 25
began treatment, patients 23 and 24 had been dosed at .a1,b3/ and .a2,b2/ respectively, and four
patients had partially completed their DLT follow-up (patients 21–24). Therefore, on the basis
of the best estimate of the MTC and safety constraints, patient 25 was assigned to .a3,b1/. This
procedure was repeated until all 40 patients had received treatment. Three MTDCs, .a1,b3/,
.a3,b2/ and .a4,b1/, were recommended at the end of the trial, with true DLT probabilities
of 0.16, 0.18 and 0.16 respectively. Nine patients out of 40 (22:5%) experienced DLTs, and
17 patients (42.5%) were treated at the recommended MTDCs. The trial duration was 19:55
time units. We also simulated a trial (using the same random-number seed) that waited for
complete follow-up from patients, as per the original PIPE design (a cohort size of two patients
per combination). This trial lasted 32:43 time units and recommended .a2,b3/ and .a4,b1/ as
MTDCs (true DLT probabilities 0.20 and 0.16 respectively). Eight patients out of 40 (20%)
experienced DLTs, and 17 patients (42.5%) were treated at the recommended MTDCs. Using
the TITE–PIPE–C design here reduced the trial duration by 12:88 time units (39:7%) and
recommended dose combinations with similar true DLT risks. Fig. 4 shows the trial progression
with the estimatedMTC and the inadmissible dose contour, as well as the trueMTC at the trial
end (the dotted line).
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4.2. Experimentation and recommendation percentages
Table 2 shows the experimentation percentages, for each simulation, assuming uniformly dis-
tributed toxicity times and a uniform weight function. Experimentation percentages are de-
pendent on λ, with increasing λ (more rapid arrival of patients) associated with more experi-
mentation at combinations with lower true probabilities of DLT. This is due to the conservative
assumption that an unobserved portion of a patient’s observationwindow is attributed to aDLT
outcome. Under the TITE–PIPE–O design, a new patient is treated at a dose under the assump-
tion that the previous patient, who has been followed up for a short amount of time, contributes
more to the number of DLTs rather than non-DLTs. However, under the TITE–PIPE–C design,
a new patient may have to wait until the minimum number of patients have completed treatment
at a particular dose. As a result, the average observedDLT rates per scenario decrease both with
increasing λ and as we move from the PIPE to the TITE–PIPE–C to the TITE–PIPE–O design;
the TITE–PIPE–C method generally offers experimentation operating characteristics that sit
between the PIPE approach and the TITE–PIPE–O approach.
Table 3 shows the chance of recommending combinations with true DLT probabilities within
different intervals per design and scenario, as well as the mean number of MTDCs recom-
mended, the percentage of trials that did not recommend any MTDCs and the percentage of
trials that were terminated early. The TITE–PIPE approaches and the PIPE design have similar
recommendation percentages within the 15–24% DLT risk interval (where the TTL lies), with
any differences between designs becoming more pronounced as λ increases. The performance
can be slightly improved, or slightly reduced by using the TITE–PIPE over the PIPE design;
in scenario A with λ=2, the chance of choosing combinations with true DLT risk of 15–24%
increases from 73% to 76% under the TITE–PIPE design, whereas in scenario B it decreases
from 27% to 18%.
The percentage of trials that terminate early increases as wemove from the PIPE to the TITE–
PIPE–C design (the largest relative increase of 1:4% (scenario C)) to the TITE–PIPE–O design
(the largest relative increase of 2:3% (scenario C)). This is because TITE–PIPE approaches are
slightly more likely to assign patients to lower dose combinations (since partially followed-up
patients contribute a partial DLT response; see Table 2), and any subsequent DLTs at lower
combinations will increase the chance of terminating the trial earlier than if those DLTs were
observed at higher combinations. Overall, the differences in early stopping probabilities between
approaches are very small. The percentage of trials that do not recommend anyMTDCs includes
those trials that terminate early and trials where all 40 patients are treated, but no MTDCs can
be identiﬁed (see Section 2.6).
When using the adaptive weighting function instead of the uniform weighting function, no
major differences are observed in experimentation or recommendation results (see the on-line
supplementary material, Table S1 and Table S2). This is not surprising; given the simulation-
generated uniformly distributed toxicity times, the adaptive weight function will yield similar
weighted DLT outcomes to those of the uniform weighting function.
4.3. Trial duration and delays in treatment
Table 4 gives the mean trial durations (and the percentage change from the PIPE design) per
design and scenario, under both uniform and adaptive weight functions. Trial durations do not
differ with the choice of weight function when assuming uniformly distributed time to toxicity.
Looking at the results from using the uniform weight function, the trial duration is shortened
under the TITE–PIPE approaches by 0.4–1.2 units (λ = 0:5), 0.8–2.2 units (λ = 1) and 3.6–
10.3 units (λ= 2). When the average arrival rate is two patients per time unit (λ= 2), the trial
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Table 2. Experimentation percentages by using the uniform weight function (assuming a uniformly distributed
DLT model)
Arrival rate λ Design Results for the following probabilities of DLT (%): Mean Mean
sample size DLTs (%)
0–14 15–24 25–34 35–45 46
Scenario A
0.5 PIPE 20 63 17 — — 40.0 19
TITE–PIPE–C 21 63 16 — — 40.0 19
TITE–PIPE–O 23 62 15 — — 39.9 19
1 PIPE 20 63 17 — — 40.0 19
TITE–PIPE–C 22 62 15 — — 39.9 19
TITE–PIPE–O 27 61 12 — — 39.9 18
2 PIPE 20 63 17 — — 40.0 19
TITE–PIPE–C 27 60 13 — — 39.9 18
TITE–PIPE–O 34 58 7 — — 39.9 17
Scenario B
0.5 PIPE 76 24 — — — 40.0 12
TITE–PIPE–C 77 23 — — — 40.0 12
TITE–PIPE–O 80 20 — — — 40.0 11
1 PIPE 76 24 — — — 40.0 12
TITE–PIPE–C 79 21 — — — 40.0 11
TITE–PIPE–O 84 16 — — — 40.0 11
2 PIPE 76 24 — — — 40.0 12
TITE–PIPE–C 83 17 — — — 40.0 11
TITE–PIPE–O 91 9 — — — 40.0 10
Scenario C
0.5 PIPE 14 15 27 33 11 39.5 31
TITE–PIPE–C 14 16 27 32 10 39.4 31
TITE–PIPE–O 15 16 27 33 10 39.1 31
1 PIPE 14 15 27 33 11 39.5 31
TITE–PIPE–C 15 16 27 32 10 39.4 31
TITE–PIPE–O 16 16 29 31 8 39.1 30
2 PIPE 14 15 27 33 11 39.5 31
TITE–PIPE–C 18 16 27 29 9 39.3 30
TITE–PIPE–O 19 18 29 28 6 39.1 28
Scenario D
0.5 PIPE — — — 57 43 19.4 61
TITE–PIPE–C — — — 60 40 19.4 61
TITE–PIPE–O — — — 61 39 19.2 61
1 PIPE — — — 57 43 19.4 61
TITE–PIPE–C — — — 63 37 19.5 61
TITE–PIPE–O — — — 64 36 19.1 61
2 PIPE — — — 57 43 19.4 61
TITE–PIPE–C — — — 66 34 19.5 61
TITE–PIPE–O — — — 69 31 19.1 60
Scenario E
0.5 PIPE 30 31 39 1 — 39.8 21
TITE–PIPE–C 30 31 39 0 — 39.8 21
TITE–PIPE–O 32 31 37 0 — 39.7 21
1 PIPE 30 31 39 1 — 39.8 21
TITE–PIPE–C 31 31 38 0 — 39.8 21
TITE–PIPE–O 34 32 35 0 — 39.7 20
2 PIPE 30 31 39 1 — 39.8 21
TITE–PIPE–C 33 30 36 0 — 39.8 20
TITE–PIPE–O 38 32 30 0 — 39.7 19
(continued)
Model-free Approach to Combination Therapy Phase I Trials 323
Table 2 (continued )
Arrival rate λ Design Results for the following probabilities of DLT (%): Mean Mean
sample size DLTs (%)
0–14 15–24 25–34 35–45 46
Scenario F
0.5 PIPE 20 55 — 14 11 39.5 25
TITE–PIPE–C 21 53 — 14 11 39.5 25
TITE–PIPE–O 22 53 — 14 10 39.3 25
1 PIPE 20 55 — 14 11 39.5 25
TITE–PIPE–C 23 52 — 14 11 39.4 25
TITE–PIPE–O 25 52 — 14 9 39.3 24
2 PIPE 20 55 — 14 11 39.5 25
TITE–PIPE–C 28 48 — 14 10 39.4 24
TITE–PIPE–O 32 49 — 14 6 39.3 23
Scenario G
0.5 PIPE 38 35 21 3 3 40.0 17
TITE–PIPE–C 40 35 20 3 2 40.0 17
TITE–PIPE–O 42 34 19 3 2 40.0 17
1 PIPE 38 35 21 3 3 40.0 17
TITE–PIPE–C 41 34 19 3 2 40.0 17
TITE–PIPE–O 45 32 18 3 2 40.0 16
2 PIPE 38 35 21 3 3 40.0 17
TITE–PIPE–C 46 33 17 2 2 40.0 16
TITE–PIPE–O 53 30 15 2 1 40.0 14
duration can be shortened by 24–33%, without substantially compromising on experimentation
and MTDC recommendation performance.
As well as reductions in trial duration, we also consider the mean delay between recruit-
ment of the last patient onto a trial and the administration of their treatment. Fig. 5 shows
that, under the PIPE design, the delay between recruitment of the last patient and treatment
administration increases substantially as the recruitment rate λ increases. For λ=0:5, this de-
lay is approximately 0.40 time units (0.16 for scenario D, where the average sample size was
around 19 patients). When λ = 1, although the mean trial duration between the PIPE and
TITE–PIPE methods is very similar, there is a noticeable difference in the mean delay in treat-
ment for the last recruited patient. When λ = 2, this delay increases dramatically to around
10 time units (3.8 time units for scenario D). Under the TITE–PIPE design, the delay is vir-
tually 0 (a maximum of 0.35 under the TITE–PIPE–C the design (scenario D) and 0.28 un-
der the TITE–PIPE–O design (scenario D)). So, as well as shortening the trial, the delay be-
tween recruitment and receiving treatment (as measured in the last patient) is almost completely
removed.
4.4. Early onset and late onset toxicities
We now assume that the time to toxicity is distributed as a Pareto random variable (Section
3.1) so that DLTs are more likely to occur earlier in a patient’s observation period than under a
uniform distribution. Tables S3 and S4 in the on-line supplementary material show similar ex-
perimentation and MTDC recommendation results to that under the uniform time-to-toxicity
distribution. Under the adaptive weight function (Tables S5 and S6), changes of 1–2% are ob-
served when comparing the TITE–PIPEMTDC recommendations with those by using uniform
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Table 3. Recommendation percentages by using a uniform weight function (assuming a uniformly distributed
DLT model)
Arrival rate λ Design Results for the following Mean Trials Trials
probabilities of DLT (%): number of with no that stopped
MTDCs MTDC (%) early (%)
0–14 15–24 25–34 35–45 46
Scenario A
0.5 PIPE 12 73 15 — — 2.3 0.2 0.2
TITE–PIPE–C 11 74 15 — — 2.2 0.2 0.2
TITE–PIPE–O 11 75 14 — — 2.2 0.2 0.2
1 PIPE 12 73 15 — — 2.3 0.2 0.2
TITE–PIPE–C 12 73 15 — — 2.2 0.4 0.4
TITE–PIPE–O 11 75 14 — — 2.2 0.2 0.2
2 PIPE 12 73 15 — — 2.3 0.2 0.2
TITE–PIPE–C 12 74 14 — — 2.2 0.3 0.3
TITE–PIPE–O 11 76 11 — — 2.2 0.8 0.6
Scenario B
0.5 PIPE 73 27 — — — 1.9 0 0
TITE–PIPE–C 73 27 — — — 1.9 0 0
TITE–PIPE–O 74 26 — — — 1.9 0 0
1 PIPE 73 27 — — — 1.9 0 0
TITE–PIPE–C 74 26 — — — 1.9 0 0
TITE–PIPE–O 76 24 — — — 1.9 0 0
2 PIPE 73 27 — — — 1.9 0 0
TITE–PIPE–C 77 23 — — — 2.0 0 0
TITE–PIPE–O 82 18 — — — 2.1 0 0
Scenario C
0.5 PIPE 16 24 35 19 1 1.3 4.5 2.1
TITE–PIPE–C 16 25 34 20 1 1.3 4.8 2.6
TITE–PIPE–O 15 22 33 21 2 1.3 6.9 4.3
1 PIPE 16 24 35 19 1 1.3 4.5 2.1
TITE–PIPE–C 14 23 35 20 2 1.3 5.6 2.8
TITE–PIPE–O 15 22 34 20 2 1.3 7.0 4.3
2 PIPE 16 24 35 19 1 1.3 4.5 2.1
TITE–PIPE–C 13 23 34 22 2 1.3 6.7 3.5
TITE–PIPE–O 14 24 32 21 2 1.2 7.9 4.4
Scenario D
0.5 PIPE — — — 3 2 — 95.8 87.2
TITE–PIPE–C — — — 2 2 — 96.2 87.0
TITE–PIPE–O — — — 2 1 — 96.5 87.8
1 PIPE — — — 3 2 — 95.8 87.2
TITE–PIPE–C — — — 2 2 — 96.0 86.8
TITE–PIPE–O — — — 2 1 — 97.0 87.5
2 PIPE — — — 3 2 — 95.8 87.2
TITE–PIPE–C — — — 2 2 — 96.3 86.4
TITE–PIPE–O — — — 2 1 — 97.7 87.5
Scenario E
0.5 PIPE 30 32 37 — — 2 0.9 0.7
TITE–PIPE–C 30 32 37 — — 2 0.8 0.7
TITE–PIPE–O 30 32 37 — — 2 1.1 1.0
1 PIPE 30 32 37 — — 2 0.9 0.7
TITE–PIPE–C 30 31 38 — — 2 0.8 0.6
TITE–PIPE–O 30 33 35 — — 2 1.1 1.1
2 PIPE 30 32 37 — — 2 0.9 0.7
TITE–PIPE–C 30 32 36 — — 2 1.2 1.1
TITE–PIPE–O 32 33 33 — — 2 1.8 1.4
(continued)
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Table 3 (continued )
Arrival rate λ Design Results for the following Mean Trials Trials
probabilities of DLT (%): number of with no that stopped
MTDCs MTDC (%) early (%)
0–14 15–24 25–34 35–45 46
Scenario F
0.5 PIPE 13 70 — 11 4 1.7 2.1 1.6
TITE–PIPE–C 12 71 — 11 4 1.7 1.9 1.5
TITE–PIPE–O 13 71 — 10 4 1.7 2.5 2.3
1 PIPE 13 70 — 11 4 1.7 2.1 1.6
TITE–PIPE–C 12 71 — 10 4 1.7 2.8 1.8
TITE–PIPE–O 13 71 — 10 4 1.7 3.0 2.3
2 PIPE 13 70 — 11 4 1.7 2.1 1.6
TITE–PIPE–C 12 70 — 11 4 1.7 3.5 2.0
TITE–PIPE–O 13 70 — 10 3 1.6 4.6 2.6
Scenario G
0.5 PIPE 44 38 17 1 0 2.7 0 0
TITE–PIPE–C 45 37 17 1 0 2.8 0 0
TITE–PIPE–O 45 36 17 1 1 2.7 0 0
1 PIPE 44 38 17 1 0 2.7 0 0
TITE–PIPE–C 44 37 18 1 1 2.7 0 0
TITE–PIPE–O 44 36 19 1 1 2.7 0 0
2 PIPE 44 38 17 1 0 2.7 0 0
TITE–PIPE–C 44 36 18 1 0 2.7 0 0
TITE–PIPE–O 45 36 18 1 1 2.7 0 0
Table 4. Mean trial durations per design and scenario, with percentage change from the PIPE design (in
parentheses) by using uniform and adaptive weight functions (assuming a uniformly distributed DLT model)
Arrival rate λ Design Durations (time units) for the following scenarios:
A B C D E F G
Uniform weight function
0.5 PIPE 79.3 (—) 79.5 (—) 78.4 (—) 38.7 (—) 79.0 (—) 78.4 (—) 79.5 (—)
TITE–PIPE–C 79.0 (0) 79.1 (−1) 78.0 (−1) 38.7 (0) 78.6 (0) 78.0 (0) 79.1 (−1)
TITE–PIPE–O 78.9 (−1) 79.1 (−1) 77.2 (−1) 38.3 (−1) 78.5 (−1) 77.8 (−1) 79.1 (−1)
1 PIPE 41.8 (—) 42.2 (—) 41.1 (—) 20.0 (—) 41.6 (—) 41.3 (—) 42.0 (—)
TITE–PIPE–C 40.0 (−4) 40.1 (−5) 39.4 (−4) 19.6 (−2) 39.8 (−4) 39.5 (−5) 40.0 (−5)
TITE–PIPE–O 39.9 (−4) 40.0 (−5) 39.1 (−5) 19.2 (−4) 39.7 (−5) 39.4 (−5) 40.0 (−5)
2 PIPE 29.8 (—) 30.8 (—) 29.1 (—) 13.6 (—) 29.7 (—) 29.5 (—) 30.1 (—)
TITE–PIPE–C 20.5 (−31) 20.6 (−33) 20.2 (−31) 10.3 (−24) 20.4 (−31) 20.2 (−31) 20.5 (−32)
TITE–PIPE–O 20.4 (−31) 20.5 (−33) 20.0 (−31) 10.0 (−26) 20.3 (−32) 20.1 (−32) 20.5 (−32)
Adaptive weight function
0.5 PIPE 79.3 (—) 79.5 (—) 78.4 (—) 38.7 (—) 79.0 (—) 78.4 (—) 79.5 (—)
TITE–PIPE–C 79.0 (0) 79.1 (−1) 77.9 (−1) 38.7 (0) 78.6 (0) 78.0 (−1) 79.1 (−1)
TITE–PIPE–O 78.9 (−1) 79.1 (−1) 77.1 (−2) 38.4 (−1) 78.5 (−1) 77.7 (−1) 79.1 (−1)
1 PIPE 41.8 (—) 42.2 (—) 41.1 (—) 20.0 (—) 41.6 (—) 41.3 (—) 42.0 (—)
TITE–PIPE–C 40.0 (−4) 40.1 (−5) 39.4 (−4) 19.6 (−2) 39.8 (−4) 39.4 (−5) 40.0 (−5)
TITE–PIPE–O 39.9 (−4) 40.0 (−5) 38.9 (−5) 19.2 (−4) 39.7 (−5) 39.3 (−5) 40.0 (−5)
2 PIPE 29.8 (—) 30.8 (—) 29.1 (—) 13.6 (—) 29.7 (—) 29.5 (—) 30.1 (—)
TITE–PIPE–C 20.5 (−31) 20.6 (−33) 20.2 (−31) 10.2 (−25) 20.4 (−31) 20.3 (−31) 20.5 (−32)
TITE–PIPE–O 20.4 (−32) 20.5 (−33) 19.8 (−32) 9.9 (−27) 20.3 (−32) 20.0 (−32) 20.5 (−32)
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weightings, but otherwise very little difference is observed. For trial durations (Table S7), we
again see similar time savings under different recruitment rates to those observed under uniform
time to toxicity. This is probably because we observe few toxicities on average per trial (between
four and 12 out of 40 patients approximately), and the mean time to DLT is similar under the
uniform and Pareto distributions used, even though the DLT times under the Pareto distribu-
tion are skewed towards earlier times. Essentially, the DLTs that do occur are clustered towards
the start of a patient’s DLT observation window, but there are not enough of them to cause a
noticeable change in model performance on the adaptive weighting function.
When the time to DLT follows a Weibull distribution, so that DLT times are skewed towards
the end of the DLT observation period (Section 3.1), we again see minimal changes in each
design’s operating characteristics. This applies to both the uniform weighting function (Tables
S8 and S9 in the on-line supplementary material) and the adaptive weighting function (Tables
S10 and S11). The trial duration (Table S12) is reduced under the TITE–PIPE approaches
regardless of which weighting function is used, and to a similar extent to that of the simulations
for uniform- and Pareto-distributed time to toxicity. The greatest reductions in duration are
slightly more than observed under a uniform time-to-toxicity model (34–35% reduction).
5. Discussion
We have proposed an approach for incorporating censored patient toxicity outcomes into the
PIPE dose escalation design for dual agent phase I trials. We have shown that substantial
reductions in trial duration can be achieved, and delays in starting treatment can be avoided even
when recruitment is at a rate that is similar to the outcome follow-up time. These can be done
without compromising on the experimentation and MTDC recommendation performance. We
found that the TITE–PIPE–C approach, where two patients had to be completely followed
up per combination experimented on before censored time-to-toxicity data could be used for
dose escalation decisions, gave slightly better experimentation performance than that of the
TITE–PIPE–O method. Furthermore, the performance of both the TITE–PIPE–C and the
TITE–PIPE–O methods was generally invariant to the underlying time-to-toxicity distribution
of the combination therapy and was not affected by the choice of weight function (uniform or
adaptive).
We implemented a safety rule that if the probability that the lowest dose combination is above
the MTC is at least 0:80, given data from patients who had completed their follow-up, then the
trial is terminated. We also implemented a probabilistic rule (Bekele et al., 2008; Polley, 2011;
Ivanova et al., 2016) whereby if, on the basis of partial data, the probability that the lowest
dose combination is above theMTC is greater than =0:80, then recruitment is suspended until
those patients who are enrolled in the trial have completed their follow-up. Then we use the
new set of completely observed data to assess whether the trial should be terminated or not.
The threshold  should be carefully considered before the design is implemented in practice; we
adopted a threshold of = 0:80 so that the trial would be terminated if the ﬁrst two patients
experienced DLTs, but higher thresholds (e.g. = 0:95) have been considered (Ivanova et al.,
2016) andmay prove more favourable for reducing the chances of terminating a trial when there
truly is at least oneMTDC. Calibration of this stopping rule will need to be performed per trial
and will vary with chosen TTLs, clinical needs and prior set-ups (median DLT risks and prior
sample sizes).
The simulation studies that were conducted show that trial duration can be reduced by 5–6%
when patients arrive at a rate of one per DLT observation window (in this study, one time unit)
and reduced up to 35% when patients arrive twice as fast as expected.
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We have focused on comparing the TITE–PIPE with the PIPE design to assess the trade-off
betweenMTDC recommendation accuracy and trial duration. Other approaches incorporating
TITE outcomes in combination therapy phase I trials have been proposed in the literature.
The partial ordering TITE–CRM design (Wages et al., 2013) recommends a single MTDC,
rather than estimating a contour. Riviere et al. (2014) proposed a TITE extension of their
Bayesian dose ﬁnding design for combination therapies that used a four-parameter logistic
model, which they compared with a non-TITE version of the same design. Our interest in
comparing two versions of the TITE–PIPE with the original PIPE design is motivated by the
use of the PIPEdesign in practice for at least two clinical trials since its publication. Investigating
an overall comparison between these designs is an area for further research, though ensuring
that appropriate simulation studies are conducted with fairly calibrated priors across different
designs is a challenge that would need to be addressed.
In summary, incorporating TITE outcomes in the PIPE dual agent dose escalation design is
easily achieved and can provide worthwhile savings with respect to trial duration with operating
performance comparable with that of the original PIPE design. We have incorporated these
functions in the latest release of the R package pipe.design.
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